Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes.: Association of CD3+CD56+ cells with platinum resistance

被引:71
作者
Bamias, A.
Tsiatas, M. L.
Kafantari, E.
Liakou, C.
Rodolakis, A.
Voulgaris, Z.
Vlahos, G.
Papageorgiou, T.
Tsitsilonis, O.
Bamia, C.
Papatheodoridis, G.
Politi, Ek.
Archimandritis, A.
Antsaklis, A.
Dimopoulos, M. A.
机构
[1] Univ Athens, Dept Obstet & Gynaecol 1, GR-10679 Athens, Greece
[2] Univ Athens, Dept Biol, GR-15701 Athens, Greece
[3] Univ Athens, Dept Hyg & Epidemiol, GR-10679 Athens, Greece
[4] Univ Athens, Dept Internal Med 2, GR-10679 Athens, Greece
[5] Univ Athens, Dept Cytopathol, GR-10679 Athens, Greece
[6] Univ Athens, Dept Clin Therapeut, GR-10679 Athens, Greece
关键词
ovarian cancer; immune response; NK-T; Tregs;
D O I
10.1016/j.ygyno.2007.02.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objectives. Tumor infiltrating lymphocytes (TILs) and T regulatory cells (Tregs) have been associated with prognosis in ovarian cancer, but then- prognostic significance in ascites has not been studied. We performed a prospective study of T lyrnphocytes isolated from ascites from patients with ovarian carcinoma and we compared them with the respective populations in blood and tumors. Methods. Mononuclear cells from ascites (n=71) and blood were isolated by Ficoll, while tumor lymphocytes (n=20) were obtained upon mechanical dissociation. Phenotypic analysis was performed with flow cytometry. Ascites from 10 patients with cirrhosis was used as control. Results. Tregs containing CD4(+)CD25(+) cells, NK-T containing CD3(+)CD56(+) cells and CD69 and HLADR expression of CD4 and CD8 lymphocytes were significantly increased in tumor ascites compared to blood and control ascites. A selective accumulation of these populations in the ascites of cancer patients, was suggested by the significantly higher ascites/blood (A/B) ratios in cancer patients but not controls. Cancer cell content in ascites was correlated with CD4(+)CD25(+), CD4(+)CD69(+), CD4(+)HLADR(+) and CD8(+)CD69(+) cells. There was no correlation of lymphocyte populations between ascites and samples from peritoneal rnetastases. Higher tumor grade was associated with increased A/B CD4(+)CD25(+) ratio and reduced CD3(+)CD56(+) cells, while platinum resistance was associated with reduced A/B CD3(+)CD56(+) ratio. Conclusions. There are significant differences of CD3(+)CD56(+) and CD25(+)CD4(+) lymphocytes and increase in lyrnphocyte activation between blood, ascites and peritoneal metastases from patients with ovarian cancer. The selective accumulation of CD3+CD56+ population in ascites may be a predictive factor for platinurn resistance. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 30 条
[1]
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers [J].
Badoual, C ;
Hans, S ;
Rodriguez, J ;
Peyrard, S ;
Klein, C ;
Agueznay, NE ;
Mosseri, V ;
Laccourreye, O ;
Bruneval, P ;
Fridman, WH ;
Brasnu, DF ;
Tartour, E .
CLINICAL CANCER RESEARCH, 2006, 12 (02) :465-472
[2]
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[3]
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].
du Bois, A ;
Lück, HJ ;
Meier, W ;
Adams, HP ;
Möbus, V ;
Costa, S ;
Bauknecht, T ;
Richter, B ;
Warm, M ;
Schröder, W ;
Olbricht, S ;
Nitz, U ;
Jackisch, C ;
Emons, G ;
Wagner, U ;
Kuhn, W ;
Pfisterer, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330
[4]
Leveraging the activity of tumor vaccines with cytotoxic chemotherapy [J].
Emens, LA ;
Jaffee, EM .
CANCER RESEARCH, 2005, 65 (18) :8059-8064
[5]
ERCOLINI A, 2005, J EXP MED, V210, P1
[6]
Feuerer M, 2001, INT J CANCER, V92, P96, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1152>3.3.CO
[7]
2-H
[8]
HIRAOKA K, 2006, BRIT J CANCER, V85, P255
[9]
Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO
[10]
2-S